Pierre Gravier Sells 2,992 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CFO Pierre Gravier sold 2,992 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total transaction of $207,525.12. Following the transaction, the chief financial officer directly owned 87,318 shares of the company’s stock, valued at $6,056,376.48. This represents a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Pierre Gravier also recently made the following trade(s):

• On Tuesday, January 6th, Pierre Gravier sold 2,139 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $164,596.05.

PTC Therapeutics Trading Up 1.1%

Shares of NASDAQ PTCT traded up $0.76 during mid-day trading on Friday, hitting $70.66. The company had a trading volume of 2,532,077 shares, compared to its average volume of 1,290,685. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The company has a market capitalization of $5.67 billion, a price-to-earnings ratio of 8.25 and a beta of 0.48. The stock’s 50-day moving average price is $75.01 and its 200-day moving average price is $67.78.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The firm had revenue of $164.68 million for the quarter, compared to the consensus estimate of $281.45 million. During the same period last year, the company posted ($0.85) EPS. The business’s revenue was down 22.7% on a year-over-year basis. As a group, equities research analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UMB Bank n.a. purchased a new stake in PTC Therapeutics during the fourth quarter valued at approximately $26,000. Smartleaf Asset Management LLC lifted its holdings in PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 236 shares in the last quarter. Optiver Holding B.V. boosted its holdings in shares of PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 249 shares during the period. Comerica Bank grew its stake in PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares in the last quarter. Finally, Salomon & Ludwin LLC purchased a new stake in PTC Therapeutics in the fourth quarter valued at about $41,000.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company reported full‑year 2025 product and royalty revenue that exceeded guidance, strong early commercial uptake of Sephience™ (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M), and $1.95B cash on hand — supports runway for commercialization and R&D. Read More.
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but kept a “buy” rating, signaling continued analyst conviction and providing potential support for the stock. Read More.
• Neutral Sentiment: Full Q4 earnings call transcript and highlights are available for investors parsing management commentary for drivers of the revenue miss (useful to judge one‑time items vs. sustained weakness). Read More.
• Negative Sentiment: Q4 results missed badly: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — revenue fell ~22.7% YoY. That miss is the primary near‑term driver of investor concern. Read More.
• Negative Sentiment: Management set FY‑2026 revenue guidance of $700M–$800M versus street consensus near $974M — a sizable downward gap that reduces near‑term upside and likely drove negative sentiment. Read More.
• Negative Sentiment: Regulatory uncertainty after PTC withdrew a Translarna NDA has prompted new questions about that program’s prospects and potential revenue contribution. Read More.
• Negative Sentiment: Insider selling: VP Mark Elliott Boulding sold ~5,894 shares across Feb. 17–18 (recent Form 4 filings), a modest but visible reduction that some investors view negatively. Read More.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Royal Bank Of Canada decreased their target price on PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating on the stock in a research note on Friday. Morgan Stanley restated an “overweight” rating and issued a $90.00 price objective on shares of PTC Therapeutics in a research report on Thursday, January 8th. Wells Fargo & Company cut their target price on shares of PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating for the company in a research report on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday, December 29th. Finally, The Goldman Sachs Group lifted their price objective on PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a report on Wednesday, November 5th. Ten investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, PTC Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $80.73.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.